Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02245737 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2,218
- Enrollment target
NCT02245737 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 2,218 participants.
The verdict
NCT02245737, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2,218 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that lanabecestat is a disease-modifying treatment for participants with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2 lanabecestat treatment groups compared with placebo.
Interventions
- DRUG Placebo
- DRUG Lanabecestat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,218 participants |
| Start Date | 2014-09-30 |
| Est. Completion | 2018-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02245737
The ClinicalTrials.gov registry entry for NCT02245737 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2,218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02245737 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02245737 about?
NCT02245737 is a clinical study titled "An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease". The purpose of this study is to assess the efficacy and safety of lanabecestat compared with placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study will test the hypothesis that lanabecestat is a disease-modifying treatment for participants with early Alzheimer´s...
What is the current status of trial NCT02245737?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2,218 participants. The study started on 2014-09-30. Estimated completion is 2018-10-04.
What interventions are being tested in trial NCT02245737?
The interventions under investigation include: Placebo (DRUG), Lanabecestat (DRUG).
Who is sponsoring clinical trial NCT02245737?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.